HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Authorized CBD Products In UK Could Be Another Two Years Away

Executive Summary

While the UK's Food Standards Agency is hopeful it can commence the safety assessment of validated novel food applications for CBD products in the next few months, it could take another two years for products to be fully authorized for sale.

You may also be interested in...



Valisure Alerts US FDA To Benzene In Dry Shampoos, Says Any Detected Level Could Be ‘Unacceptable’

Valisure found 70% of 148 tested dry shampoo batches contained ‘quantifiable’ benzene. The US FDA advises a strict 2ppm limit when benzene’s use is unavoidable to produce a drug product with a “significant therapeutic advance.” In dry shampoos, “any significant detection of benzene could be deemed unacceptable,” Valisure suggests in its 31 October citizen petition to the agency.

UK CBD Industry Vexed As FSA Publishes Searchable Public List – A Year Late

The UK Food Standards Agency has published its much anticipated searchable, online CBD public list. But after a long wait, the list's publication has triggered a wave of anxiety and criticism from CBD firms and experts. 

NPA Petitions US FDA To Act On CBD Regulation

NPA head Daniel Fabricant's disappointment about FDA inaction grow as UK makes progress in regulating CBD products. Either deem CBD lawful, or start testing ingredients' safety or conduct rulemaking, NPA urges.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152047

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel